Trials / Terminated
TerminatedNCT03207815
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Noninfectious Uveitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgotinib | Tablet(s) administered orally |
| DRUG | Placebo to match filgotinib | Tablet(s) administered orally |
| DRUG | Prednisone | Tablet(s) administered orally |
Timeline
- Start date
- 2017-07-26
- Primary completion
- 2020-12-29
- Completion
- 2021-04-22
- First posted
- 2017-07-05
- Last updated
- 2022-01-21
- Results posted
- 2022-01-21
Locations
24 sites across 7 countries: United States, Australia, Canada, Germany, Israel, New Zealand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03207815. Inclusion in this directory is not an endorsement.